1RODEGHIERO F,STASI R,GERNSHEIMER T,et al.Standardization of terminology,definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group[J].Blood,2009,113:2386-2393. 被引量：1
4GUPTA R,SOUPIR C P,JOHARI V,et al.Myelodysplastic syndrome with isolated deletion of chromosome 20q:an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation[J].Br J Haematol,2007,139:265-268. 被引量：1
5VESELY S K,PERDUE J J,RIZVI M A,et al.Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy:a systematic review[J].Ann Intern Med,2004,140:112-120. 被引量：1
6BURZYNSKI J.New options after first-line therapy for chronic immune thrombocytopenic purpura[J].Am J Health Syst Pharm,2009,66:S11-21. 被引量：1
7DIERICKX D,VERHOEF G,VAN HOOF A,et al.Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura:a Belgian retrospective multicentric study[J].J Intern Med,2009,266:484-491. 被引量：1
8COOPER N,STASI R,CUNNINGHAM-RUNDLES S,et al.The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura[J].Br J Haematol,2004,125:232-239. 被引量：1
9PENALVER F J,JIMENEZ-YUSTE V,ALMAGRO M,et al.Rituximab in the management of chronic immune thrombocytopenic purpura:an effective and safe therapeutic alternative in refractory patients[J].Ann Hematol,2006,85:400-406. 被引量：1
10STASI R,PAGANO A,STIPA E,et al.Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura[J].Blood,2001,98:952-957. 被引量：1
2Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group [ J ]. Blood, 2009, 113( 11 ) :2386-2393. 被引量：1
4Stasi R, Amadori S, Osborn J, et al. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia [ J ] . PLos Med, 2006, 3 : e24. 被引量：1
5British Committee for Standard in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura (ITP) in adults, children and in pregnancy [ J ]. Br J naematol, 2003, 120(4) :574-596. 被引量：1
6George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods of American Society of Hematology [ J ]. Blood, 1996, 88(1) : 3-40. 被引量：1
7Cines DB, Bussel JB. How I treat-thrombocytopenic purpura (ITP) [J]. Blood, 2005, 106(7) : 2244-2251. 被引量：1
8Cortelazzo S, Finazzi G, Buelli M, et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura [J]. Blood, 1991,77(1): 31-33. 被引量：1
9Stasi R, Pagano A, Amadori S. Rituximab chimeric anti- CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenie purpura [J]. Blood, 2001,98 (4) :952-957. 被引量：1
10Giagounidis AA, Anhnf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti- CD20 monoclonal antibody rituximab: a pilot study [ J ]. Eur J Haematol, 2002, 69(2):95-100. 被引量：1
